Omar AbdiHamid/Linkedin
Nov 3, 2023, 12:19
Omar AbdiHamid: Our study on biomarkers of Immunotherapy response
Quoting Omar AbdiHamid, Clinical Oncology Specialist at HCGCCK Cancer Centre, on LinkedIn:
”Publication Alert. Our study on biomarkers of Immunotherapy response showed that high neutrophil lymphocyte ratio (NLR) and Platelets lymphocyte ratio (PLR) either at baseline or during treatment is associated with poorer treatment outcome. Therefore, these ratios can be utilized in clinical practice with other markers to determine treatment efficacy from immunotherapy.”
For the article click here.
Source: Omar AbdiHamid/LinkedIn
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 23, 2024, 15:26
Dec 23, 2024, 15:13
Dec 23, 2024, 15:10
Dec 23, 2024, 14:55
Dec 23, 2024, 14:52